Series A · Biotech · London, United Kingdom · Founded 2018 · 26–50 employees
Mytos builds fully automated robotic systems for manufacturing human cells, solving a critical bottleneck in biotech where manual cell production slows drug development. Their iDEM technology automates the entire cell culture process from stem cells to specialized neurons and heart cells over multiple weeks, reducing labor by 10x and cleanroom footprint. The company has secured manufacturing deals for neurons treating Parkinson's disease and raised $19M Series A in November 2023 led by Buckley Ventures. Founded by Y Combinator alumni, Mytos is expanding globally with plans for distributed manufacturing hubs to make regenerative medicine therapies accessible worldwide.